Quartesian LLC Executes Multi-Year Enterprise Agreement with Medrio, Securing Access to Innovative eClinical Functionality and Support Services

Share Article

The agreement equips the CRO with a strong eClinical asset as they work to deliver top-quality services to clinical trial sponsors.

Medrio eClinical logo
"The Medrio system will be a key asset in our efforts to compress timelines, reduce costs, and improve data cleanliness in our clinical trials, enabling us to deliver top-quality services to our clients." Stephen Boccardo, Senior VP of Business Development and Commercial Strategy, Quartesian

Quartesian LLC, a full-service contract research organization (CRO) providing data management, biostatistics, and other services to clinical trial sponsors, has entered into a multi-year agreement with Medrio, a leading provider of eClinical technology for clinical trials. The agreement will enable Quartesian, a member of Medrio’s Certified Partner Program, to leverage the full range of Medrio’s products including EDC, eConsent, ePRO, and Direct Data Capture (DDC) to support their clients in the emerging growth biotech and pharma spaces.

“The Medrio system will be a key asset in our efforts to compress timelines, reduce costs, and improve data cleanliness in our clinical trials, enabling us to deliver top-quality services to our clients and free up resources to work more productively,” commented Stephen Boccardo, Senior Vice President of Business Development and Commercial Strategy at Quartesian. “We fully expect our partnership with Medrio over the course of this agreement to be fulfilling and mutually beneficial.”

The agreement also enables Quartesian, as a member of the Medrio Partner Program, to access a wide range of exclusive support services geared toward facilitating new connections between CROs and study sponsors. “We’re excited to announce this multi-year partnership between Quartesian and Medrio,” commented Steve Geffon, Chief Commercial Officer at Medrio. “By leveraging the functionality of Medrio’s eClinical platform and the support services of the Certified Partner Program, we expect Quartesian to be successful in exceeding their corporate objectives.”

About Quartesian LLC
Quartesian LLC was formed in January 2003 and is headquartered in Princeton, N.J. with the goal of providing “Clinical Data Your Way” to its clients. This goal is accomplished by providing clinical data services faster, more efficient and cost-effective than ever thought possible. The founding members of Quartesian rely not only on their technical expertise, but also on their experience as past clients of clinical service providers. Quartesian prides itself on its flexibility, responsiveness, adherence to client specifications and timelines for all projects conducted anywhere in the world. We have worked for over 100+ pharmaceutical, biotechnology and medical device companies with 100% repeat business and no change orders.

About Medrio
Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company's cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit medrio.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicholas O'Brien
Visit website